Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Clinical evidence

APC-APN-201

26 evidence topics · 2 sources

Objective
Location and study date
Study design
Registered design details
Eligibility criteria
Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • Design: open-label, 6-week phase 2 study with no placebo arm; the arms differ only in concomitant GLP-1 receptor agonist use, while the registry lists the allocation as randomized.
  • Size: 40 participants at 4 U.S. sites, with 22 receiving AD109 alone and 18 receiving AD109 with a GLP-1 receptor agonist, against about 20 planned per arm.
  • Population: ages 18 to 75, BMI 27 to 43 (men) or 45 (women) kg/m2, and REI4 above 5 and below 45 on home sleep apnea testing. Exclusions included bothersome insomnia or bladder outlet obstruction, narrow angle glaucoma, and prior gastric weight loss surgery. Prior device users enrolled after 2 weeks without use.
  • Endpoints: the primary outcome was spontaneously reported adverse events. Efficacy was the proportion with at least 50% REI4 reduction on home sleep apnea testing at week 5, reported as 33.3% and 29.4%.
  • Reporting: results are available only from a congress abstract, without baseline characteristics or PROs.
  • Sponsor: the abstract states the study was supported by Apnimed.